Increase in cancer incidence in younger birth cohorts [3] by Bonneux, L.G.A. (Luc) et al.
1409THE LANCET
An exercise test showed normal working capacity and no signs of
coronary artery disease. Standard 12-lead ECG was still normal.
Haemoglobin returned to normal within 2 weeks. After follow-up
for 9 months, he has had no further signs or symptoms of heart
failure.
This patient had an acute febrile illness followed by a rash, slight
haemoglobin fall, and temporary heart failure. Recent parvovirus
B19 infection was suspected and serologically confirmed. No other
causes of heart failure, such as coronary artery disease or
cardiomyopathy, were found. The anaemia was not thought to be
important. We suggest that parvovirus B 19 may be another cause of
heart failure and should be looked for in similar cases.
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Increase in cancer incidence in younger birth
cohorts
SIR,-Professor Adami and colleagues’ conclusion (March 27,
p 773) that cancer risks are increasing in younger birth cohorts in
Sweden, is based on a misinterpretation of age-period-cohort
models.l,2 Age-period-cohort models cannot be used to attribute
trends to either birth cohorts or period influences. The assumption
that first and last period effects are equal to zero is made to reach a
mathematical solution, and is arbitrary but vital to their argument.
In the text and abstract of their reports cited by Adami, Clayton and
Schifflers warn explicitly against the interpretation and
presentation of regular trends as they are in Adami’s fig 3. By
altering the arbitrary central assumption, any regular cohort trend
may be changed in a regular period trend, and vice versa. Adami’s
conclusions are therefore unsupported.
What remains is the signalled incidence increase during 1958-87.
Although standardised incidence increased by 55 % (men) and 30%
(women) in these years, standardised mortality over the same period
changed by + 3-6% (men) and -10% (women).3 If we accept
Adami’s argument that this change is entirely attributable to
therapeutic improvements, an additional 49% of male and 44% of
female cancer patients would have been cured during 1958-87.
Most cancers are solid tumours of the breast and of the respiratory,
gastrointestinal, and genitourinary tracts. Although progress has
been made, there is no evidence whatsoever to support such a
striking increase of therapeutic efficacy.
Earlier and more diagnoses are more likely to explain most of the
improvements in prognosis. Adami himself showed a strong breast
cancer survival increase in the 1970s, arguing that this trend
corresponded with increased awareness of the advantages of early
diagnosis ."* No official screening policy was adopted, but this did not
imply that all Swedish doctors disregarded the advice of the leading
cancer societies or that Swedish people did not hear about the
alleged advantages of early cancer detection. The argument that
increased diagnostic efforts are not likely to produce the alleged
cohort effects demonstrates again the risk of sophisticated statistical
models more than anything else. As emphasised by Clayton and
Schiffiers, regular trends cannot be attributed to cohort or period
effects.2
All cancer registers consistently show more favourable disease
stages among younger birth cohorts, but at a price: earlier diagnosis
means diagnosis at a younger age (lead time), of more slowly
growing tumours which previously would have passed unnoticed
(length time), and of early, hard to classify, lesions with an uncertain
natural history (intestinal borderline polyps, bladder papilloma,
early stage gastric and prostatic cancer, and so on). All will increase
incidence, and bias estimates of underlying cancer risks. By
applying sophisticated statistical models only to incidence or only to
mortality, highly relevant information is neglected. We suggest that
all available evidence should be examined to understand time
trends: incidence, mortality, and prognosis.s
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SiR,&mdash;Professor Adami and colleagues’ report shows the value of
recording high-quality data over many years. The reported
increases in the incidence of cancer in Sweden are large and
generally consistent over the 30-year and the 80-year intervals, and
Adami et al favour a direct link with changes in exposure to
carcinogenic hazards. However, there is another hypothesis that
would explain these increases.
Age-specific incidence is necessarily based on the chronological
ages of individuals and it is assumed that chronological age parallels
biological age. Other Swedish data suggest otherwise. Data for
Swedish girlsl show that age of menarche has fallen linearly from
about 15-8 years in 1885 to about 13-0 years in 1968. In 1885 most
girls with a chronological age of 14 years were prepubertal; in 1968
most girls aged 14 years were menstruating and were much more
biologically mature. If we assume that menarche occurs at a set
biological age, then the acceleration in biological age compared with
chronological age is 0-0023 years per elapsed year per year of age for
individuals. The rate of maturation has increased steadily in
childhood and this pace, once set, probably continues throughout
the lifespan.
Other evidence for increased rates of biological development, or
biological ageing, comes from Swedish studies on the growth of
children. Ljung and co-workers2 have shown that the average
prepubertal girl aged 10 years in 1968 was the same height as the
average prepubertal girl aged 11 -9 years in 1883. If height reflects
biological age, then this change is an acceleration of biological ageing
by 0-0020 years per elapsed year per year of age, which is very close
to the rate calculated with age of menarche. For boys, the
acceleration in biological age based on increased height growth was
0-0026 years per elapsed year per year of age.
This apparent acceleration in biological age compared with
chronological age has been used to recalculate the expected
age-specific incidence of cancer over the 30 years from 1958 to 1987.
I have used the reported death rates from cancer for Sweden
published by WHO.3 Adami and co-workers have shown that these
death rates differ from the incidence rates, but should approximate
them. In the table, I have assumed that biological age equalled
chronological age at the start of the 30 years, but that by the end of
this period the biological age must exceed the chronological age.
The expected incidences are calculated from biological ages.
The expected increase in the age-specific death rates from cancer
due to the relative increase in biological age was 15% in young
women, but close to 30% in older women. The expected
age-specific increase in men aged 15-25 years was 6%, but in older
men almost 50%. These predicted increases, based on increased
biological ageing, are closely similar to those of Adami and
co-workers for women, except in old age. The increases in men are
higher than in Adami’s fig 1, but the differences between men and
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EXPECTED CHANGES IN AGE-SPECIFIC INCIDENCE OF CANCER
DUETO INCREASED BIOLOGICAL AGEING
Biol = biological.
When mortality rate from cancer is calculated on basis of biological age, the increase
in biological age associated with acceleration of maturation and growth produces
increases m incidence of cancer at any chronological age.
women in this calculation are similar to the longer term increases
shown in their fig 3.
There is another feature of the Adami data that supports the
biological ageing hypothesis. They showed that men and women
aged about 40 years in 1987 had almost no increase in the incidence
of cancer. These people passed through their childhood in the years
after World War II, when conditions were not easy for parents and
children. If good environmental and social conditions lead to
increased growth, health, and maturation, then these 40-year-old
individuals may have been deprived as children and their lower
incidence of cancer would result from the resulting slower growth
and maturation. Data on their growth during childhood and their
age at menarche would support or refute that idea.
I suggest that biological age does not necessarily parallel
chronological age. Although it is usually impracticable, changes in
disease incidence might be better based on biological rather than
chronological age. Good conditions during childhood are associated
with more rapid growth and earlier maturation. The associated
increased rate of biological ageing may then lead to earlier malignant
disease. If this hypothesis is correct, then we have the paradox that a
good social and physical environment may lead to more cancer,
whereas a bad environment protects.
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Authors’reply
SIR,-Although the use of age-period-cohort models needs
considerable care and awareness of the limitation of the models, the
situation is not as bleak as Dr Bonneux and colleagues indicate.1-5
Indeed, such models are important in the analysis of incidence or
mortality trends. In our original report we had full discussion of the
methodological limitations inherent in these models, but a few
additional comments seem warranted.
Age-period-cohort modelling can be divided into two steps. The
first involves testing of various submodels against the full age-
period-cohort model. This part of the analysis is fairly
straightforward, since traditional statistical considerations usually
allow the choice of the best model. In our data, we found that the
age-cohort model was sufficient for women. For men, the full model
was an improvement on both the age-period and the age-cohort
model, but cohort seemed to be a more important factor than
period.
The second step of the modelling consists of an estimation of the
relative risks from the model identified in the first step. In our data,
this scheme caused no difficulties for women, since we could use the
age-cohort model, which has uniquely defined variables (although
they could still be biased if there was a true period effect). For men
the situation was more difficult, since the linear parts of a full model
are not uniquely identified. As we noted in our report, all choices of
further restrictions to force unique index estimates have drawbacks.
Our choice of a linear period effect with slope zero was based on the
arguments of Holford.3-5 This assumption has the further
advantage that it is almost equivalent to the method suggested by
Clayton and Schifilers.1,2 A possible result of this choice is that the
cohort effect is somewhat exaggerated, because it may include part
of the period effect. The only real alternative is to report no
estimates at all, or to report several different sets of estimates, each
based on specific assumptions. Such an approach needs to be
considered when it is unclear which of the factors are more
important, a situation we were able to avoid for men because of the
clear importance of the cohort effects. Thus it is incorrect to deny
the presence of the strong cohort effects in our data.
To what extent are incidence rates influenced by factors other
than changes in carcinogenic exposure and disease occurrence? It is
possible that screening, new diagnostic technologies, increased
diagnostic intensity, drifts in histopathological criteria, and
changing necropsy rates might result in earlier diagnosis or even
overdiagnosis of cancer; these factors could perturb incidence
trends, but only overdiagnosis can lead to sustained increases in
incidence in the absence of an increase in true cancer incidence.
Nevertheless, there is virtually no empirical evidence to support an
important role for any of these possibilities. Hence, there is a
substantial burden of proof for those who claim that they are
quantitatively important.
All quantitative methods used to assess the burden of cancer have
advantages and disadvantages.6 Comparison of the incidence, and
mortality and survival rates from the same setting are by definition
mutually dependent. In fact, the decrease in case fatality estimated
by Bonneux et al (and dismissed by them) agrees fairly well with our
estimates for Sweden during the period 1960-84.’’ However,
Bonneux and colleagues are incorrect in stating that we have
claimed improved treatment accounts for the decreased cancer case
fatality in Sweden. In fact, we have repeatedly stated that we believe
other factors probably play the more important part.6,7
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Neonatal myoclonus and neuroblastoma
SIR,-Myoclonus occurs in various disorders in neonates but,
to our knowledge, neonatal myoclonus has never been reported in
association with neoplasms, in contrast to myoclonic
encephalopathy of infancy.3 We report a newborn baby with
myoclonus who was found to have a neuroblastoma.
A 3740 g baby girl, who was born uneventfully at 39 weeks’
gestation, developed myoclonic jerks in her sleep on the third day
after birth. The cluster of jerks consisted of symmetrical rapid
movements of the arms and/or legs that lasted for several minutes.
